Program
Amphotericin B
Also written as “Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)”, “Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)” and “Amphotericin B Liposome”.
Its studies are mostly in Meningitis, Cryptococcal · Invasive Fungal Infections · Leishmaniasis, Visceral · Aspergillosis · Candidiasis, led by 9 companies.
Drug pageAmphotericin B: every studyMany companies study it; this page follows only the 14 they lead. All 89 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 60 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Alkermes | 10 open or running | phase 1since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Aurobindo Pharmaits history only | 10 open or running | phase 1since Aug 6, 2018 | Aug 6, 2018 | none ahead |
| Bristol-Myers Squibbits history only | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Johnson & Johnsonits history only | 10 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Liposomeits history only | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Matinas BioPharma Nanotechnologiesits history only | 10 open or running | phase 2since Nov 16, 2015 | Nov 16, 2015 | none ahead |
| Merckits history only | 10 open or running | phase 2since Feb 5, 2004 | Feb 5, 2004 | none ahead |
| Sichuan Huiyu Pharmaceuticalits history only | 10 open or running | no phasesince Apr 30, 2025 | Apr 30, 2025 | none ahead |
Also a collaborator on its studies: Axis Clinicals.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Alkermes only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: phase 1 study in Meningitis, CryptococcalFirst studyNCT00002316 · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Ergosterol sequestering agent”ChEMBL 37, by rule
Studies
The one study Alkermes leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00002316Meningitis, Cryptococcal · United States | 1 | Completed |
How it is read
Names in the registry
- “Amphotericin B”, 11 entries
- “Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)”, 1 entry
- “Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)”, 1 entry
- “Amphotericin B Liposome”, 1 entry
- “Comparator: amphotericin B”, 1 entry
Conditions, from the studies’ own filings
- Meningitis, Cryptococcal, 7 studies
- Invasive Fungal Infections, 1 study
- Leishmaniasis, Visceral, 1 study
- Aspergillosis, 1 study
- Candidiasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.